Sandoz Group Ltd SDZ

GRFS vs. SDZNY: Which Stock Is the Better Value Option?

As more psychedelic drugs move toward market, developers are testing how far patent protection can extend around familiar compounds.

Sandoz’s chief commercial officer discusses the company’s ambitious plans to have a biosimilar-driven growth engine by 2040.

Sandoz Group (SWX:SDZ) has moved back into focus after partnering with mAbxience on a proposed emicizumab biosimilar for hemophilia A, adding another rare disease project to its global generics and biosimilars portfolio. Recent announcements around GLP-1 products, fresh bond issuance in Europe and new biosimilar capacity in Slovenia have arrived during a mixed stretch for Sandoz Group, with a 30-day share price return down 7.07% but a 1-year total shareholder return of 44.28% that points to...

mAbxience will lead the development and production of the biosimilar candidate at its manufacturing facilities in Argentina and Spain.

mAbxience, a majority-owned company of Fresenius SE & Co. KGaA (XETR: FRE) (OTCM: FSNUY) with partial ownership from Insud Pharma; and Sandoz (SIX: SDZ) (OTCQX: SDZNY), the global leader in affordable medicines, today announced a licensing, development, manufacturing and commercialization agreement for an emicizumab biosimilar candidate. The collaboration agreement combines mAbxience's proven development and manufacturing capabilities with Sandoz's global commercial reach, creating a pathway to

Sandoz wants its portfolio to include more than 100 biosimilars by 2040, up from the 13 it has now.

GRFS vs. SDZNY: Which Stock Is the Better Value Option?

Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.

Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.

On August 17, 2026, Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has entered into a strategic collaboration with Sandoz (SIX: SDZ; OTCQX: SDZNY), a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius. The parties have also signed collaboration terms for an initial three agreed products and an option for one additional asset.